Scholars Central

Conference abstractPublished 21 Nov 2018

The evolving landscape of pre-approval access to orphan drugs

Authors: Stuart Bell

VP Consulting, UK

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

This presentation will cover the evolution over the last 10 years of pre-approval access (expanded access/early access/compassionate use/named patient supply) to drugs, with an emphasis on orphan drugs and rare diseases. • The presentation will include; • How has the landscape changed over the last 10 years? • What are the driving forces behind these changes? • How have the regulations changed in recent years, and what has the impact been? • What are the commercial opportunities provided by pre-approval access to orphan drugs? • What do the next 5-10 years hold for pre-approval access to orphan drugs?

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Genetic Syndromes & Gene Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Genetic Syndromes & Gene Therapy
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Stuart Bell”